Peptides for Eye Health — Dry Eyes, Corneal Healing & Macular Support

How peptide Targets Peptides for Eye Health

The eye is an immunologically privileged organ with limited regenerative capacity, which makes it both a challenging and promising target for peptide therapies. Thymosin Beta-4 (TB4) is the most studied peptide in ophthalmology — it promotes corneal epithelial cell migration, reduces inflammation, and inhibits corneal scarring. RegeneRx Biopharmaceuticals developed RGN-259, a sterile TB4 eye drop formulation, which completed Phase III trials for dry eye disease showing statistically significant improvements in corneal fluorescein staining scores versus placebo. TB4 also has clinical data for neurotrophic keratitis, a condition where corneal nerves degenerate, leading to impaired healing.

GHK-Cu, known primarily for skin remodeling, has broader tissue-repair properties — it stimulates collagen synthesis, glycosaminoglycan production, and angiogenesis while reducing oxidative damage. These mechanisms are relevant to corneal wound healing and age-related macular degeneration (AMD), though direct ophthalmic clinical trials with GHK-Cu are sparse. LL-37, a human cathelicidin antimicrobial peptide, has dual relevance: it provides broad-spectrum antimicrobial protection against ocular surface infections and modulates inflammatory signaling. Preclinical studies show LL-37 can reduce corneal inflammation and promote epithelial healing in animal models of bacterial keratitis.

Important context: most ophthalmic peptide applications are still in clinical development or preclinical stages. Standard dry eye treatments (artificial tears, cyclosporine, lifitegrast) and AMD therapies (anti-VEGF injections) remain first-line. Peptides represent a potential next generation of ocular therapeutics, not a replacement for current evidence-based care.